Nuvectis Pharma (NVCT) Return on Capital Employed (2022 - 2026)

Nuvectis Pharma has disclosed Return on Capital Employed across 5 years of filings, most recently posting 162.68% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 162.68%, down 2424.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 162.68% (down 2424.0% YoY), and the FY2025 annual result was 232.46%, down 3403.0% from the prior year.
• Return on Capital Employed came in at 162.68% for Q1 2026 at Nuvectis Pharma, down from 135.49% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 97.75% in Q3 2022 to a low of 218.99% in Q4 2024.
• The 5-year median for Return on Capital Employed is 141.49% (2023), against an average of 146.66%.
• Across the five-year window, Return on Capital Employed tumbled 5234 bps in 2024 and surged 8350 bps in 2025, its largest moves.
• Nuvectis Pharma's Return on Capital Employed stood at 116.93% in 2022, then sank by 43 bps to 166.65% in 2023, then plunged by 31 bps to 218.99% in 2024, then soared by 38 bps to 135.49% in 2025, then decreased by 20 bps to 162.68% in 2026.
• The last three Return on Capital Employed figures came in at 162.68% (Q1 2026), 135.49% (Q4 2025), and 133.9% (Q3 2025), per Business Quant data.